ERBB2 and neoplasm: Notably, the triple combination exhibited more pronounced effects on HER2 mRNA and protein expression levels in tumor tissues compared with CDK4/6 inhibitor combined with endocrine therapy alone (P < 0.01) (Fig. 5E, F).